Finished Dosage Forms vs. APIs: What’s the Difference in Pharmaceutical Manufacturing?
Explore the key differences between Finished Dosage Forms (FDFs) and APIs in drug development and manufacturing.
Upperton Pharma Solutions Named One of The Sunday Times Best Places to Work 2025
We’re delighted to announce that Upperton has officially been accredited as one of The Sunday Times Best Places to Work 2025
Upperton Continues Strategic Growth with the Appointment of Michael Mellor-Clark as Chief Commercial Officer.
Upperton continues growth with appointment of Michael Mellor-Clark as Chief Commercial Officer.
Upperton Announced as ‘Excellence in Innovation’ Finalist in Medilink Midlands Business Awards 2025
We are delighted to share that we have been shortlisted as a finalist in the Excellence in Innovation category at the Medilink Midlands Business Awards 2025.
CMC Considerations for Early-Stage Drug Development
Addressing CMC considerations early in the drug development process is vital in the successful creation of a pharmaceutical product.
What is CMC in Pharmaceutical Development?
CMC refers to the set of activities that ensure a drug product is consistently produced, controlled, and meets the required quality standards.
CMC in the Drug Development Process
Without a strong CMC strategy, even a promising drug candidate can fail to reach the market. Discover the foundation for product development.
Navigating CMC Regulatory Requirements in the Drug Development Process
The CMC section of a regulatory submission is essential as it ensures that the final product can be manufactured consistently and reliably.
Our GMP Manufacturing Capabilities
Home / Resources / Media Our GMP Manufacturing Capabilities
Optimising Manufacturing for Clinical Supplies in First-In-Human Trials
Manufacturing clinical supplies for a first-in-human (FIH) trial is a crucial milestone in drug development. Discover more in our guide.